Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc (ALNY) carries a ŷRobot AI score of 41 out of 100. The model's fair value estimate is $152.66, 7.5% below the last close of $165.04. The chart signal reads Hold.
| Metric | ALNY |
|---|---|
| AI score | 41 / 100 |
| Chart signal | Hold |
| Fair value estimate | $152.66 |
| Upside to fair value | -7.5% |
| Previous close | $165.04 |
| P/E | 8.33 |
| Price / sales | 4.22 |
| Market cap | $21.41B |
| EPS | 19.80 |
| Revenue growth | 38.3% |
| 1-year price change | 11.2% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about ALNY
Is ALNY overvalued or undervalued right now?
As of Nov 2, 2026, ŷRobot's fair-value model estimates Alnylam Pharmaceuticals Inc (ALNY) at $152.66 against a last close of $165.04, implying 7.5% downside to the model's estimate.
Is ALNY's chart signal bullish or bearish?
The chart-signal model classifies ALNY as Neutral as of Nov 13, 2026, with a signal score of 0.06 on a -1 to 1 scale.
What is ALNY's ŷRobot AI score?
ALNY scores 41 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is ALNY stock expensive on P/E and P/S?
ALNY trades at 8.3 times earnings and 4.2 times sales as of Nov 13, 2026.
What does ALNY's seasonal forecast show?
ŷRobot's seasonal forecast curve for ALNY reads -0.5% at 30 days, -4.9% at 90 days, and +11.2% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ALNY growing?
Alnylam Pharmaceuticals Inc's revenue growth is +38.3% and free-cash-flow growth is +84.5% on the latest reported figures.
ALNY chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.